| Literature DB >> 27668038 |
Rosa Martha Perez-Gutierrez1, Abraham Heriberto Garcia-Campoy1, Alethia Muñiz-Ramirez2.
Abstract
Six new flavonoids 2',4'-dihydroxyEntities:
Year: 2016 PMID: 27668038 PMCID: PMC5030410 DOI: 10.1155/2016/9156510
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1New compounds isolated from Eysenhardtia polystachya.
Figure 3Known compounds isolated from Eysenhardtia polystachya.
1H NMR and 13C NMR spectral data for compounds 1–4 (δ in ppm, J in Hz).
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
| 7.50 (1H, d, 15.8) | 141.31 | 4.70, d, (1H, 7.5) | 78.65 | 4.72, d, (1H, 7.5) | 78.85 | — | — |
|
| 8.24 (1H, d, 15.8) | 130.60 | 2.99, dd, (1H, 16.7, 3.0) | 41.00 | 3.02, dd, (1H, 16.7, 3.0) | 41.00 | — | — |
|
| — | — | 2.81, dd, (1H, 16.7, 13.2) | — | 2.82, dd, (1H, 16.7, 13.2) | — | — | — |
| C=O | — | 202.69 | — | 204.20 | — | 204.20 | — | — |
| 1 | — | 142.55 | — | 128.49 | — | 128.82 | — | — |
| 2 | 7.12 (2H, m, H-2, 6) | 128.43 | 7.22 (1H, dt, 8.5, 2.0) | 131.38 | 7.26 (1H, d, 2.0) | 114.81 | — | 198.21 |
| 3 | 126.57 | 6.71 (1H, dt, 8.5, 2.0) | 116.27 | — | 144.61 | 7.97, d (1H, 10.1) | 143.48 | |
| 4 | 7.46 (3H, m, H-3, 4, 5) | 126.46 | — | 164.03 | — | 145.05 | 7.70, d (1H, 10.1) | 126.71 |
| 4a | — | — | — | — | — | — | — | 105.97 |
| 5 | 128.57 | 6.51 (1H, dd, 8.5, 1.9) | 114.86 | 7.0 (1H, d, 8.0) | 114.59 | — | 143.48 | |
| 6 | 130.60 | 7.26 (1H, dd, 8.5, 2.0) | 130.16 | 7.67 (1H, dd, 8.0, 2.0) | 146.64 | 6.47, s | 106.82 | |
| 7 | — | 163.17 | ||||||
| 8 | 105.07 | |||||||
| 8a | 159.82 | |||||||
| 1′ | — | 103.79 | — | 120.52 | — | 104.76 | — | 204.21 |
| 2′ | 6.92 (1H, s, OH-2′) | 157.57 | — | 164.03 | — | 164.13 | 7.32, d (1H, 15.4) | 142.53 |
| 3′ | 6.52 (1H, d, | 114.82 | 6.68, s | 111.30 | — | 107.88 | 7.47, d (1H, 15.4) | 132.26 |
| 4′ | 6.81 (1H, s, OH-4′) | 148.36 | — | 144.59 | — | 165.34 | — | 132.68 |
| 5′ | 6.42 (1H, dd, 8.6, 2.4) | 107.52 | 6.44 (1H, d, 8.9) | 108.67 | 6.68, s | 162.45 | 6.27, 1H, m | 107.14 |
| 6′ | — | 161.21 | 7.71 (1H, d, 8.9) | 131.78 | — | 164.04 | — | 163.56 |
| 7′ | 6.32 (1H, dd, 1.7, 1.7) | 106.29 | ||||||
| 8′ | — | 166.12 | ||||||
| 9′ | 6.40, 1H, m | 101.23 | ||||||
| 1′′ | Glc-6: 5.02 (1H, d, 7.4) | 106.19 | Glc-2: 5.02 (1H, d, 7.3) | 106.12 | Glc-3: 4.85 (1H, d, 7.5) | 106.07 | Rham-1: 5.05, brs | 100.8 |
| 2′′ | 3.51 (1H, m, H-2′′, 3′′) | 78.36 | 3.53 (1H, m, H-2′′, 3′′) | 78.84 | 3.79 (1H, t, 11.0) | 74.73 | 3.89, m | 71.50 |
| 3′′ | 75.59 | 74.02 | 3.55 (1H, m) | 78.85 | 3.12, m | 71.62 | ||
| 4′′ | 3.43 (1H, m, H-4′′, 5′′) | 71.82 | 3.44 (1H, m, H-4′′, 5′′) | 71.81 | 3.5 (1H, m) | 70.27 | 3.12, m | 72.76 |
| 5′′ | 71.17 | 71.23 | 3.43 (1H, m) | 77.32 | 3.89, m | 68.32 | ||
| 6′′ | 3.88 (2H, dd, 2.0, 12 H-6′′) | 66.11 | 3.78 (2H, dd, 2.0, 12 H-6′′) | 61.33 | 4.30 (2H, dd, 2.0, 12 H-6′′) | 61.33 | 1.15 (3H, d, 7.0) | 17.98 |
| 1′′′ | Glc-6: 5.01 (1H, d, 7.3) | 104.75 | ||||||
| 2′′′ | 3.52 (1H, m, H-2′′′, 3′′′) | 78.65 | ||||||
| 3′′′ | 74.03 | |||||||
| 4′′′ | 3.44 (1H, m, H-4′′′, 5′′′) | 71.25 | ||||||
| 5′′′ | 78.01 | |||||||
| 6′′′ | 3.88 (2H, dd, 2.0, 12 H-6′′′) | 62.16 | ||||||
| OMe | 3.85, s | 56.78 | 3.39, s, 3.46, s | 60.69, 55.79 | ||||
| OH-4 | 9.10, s | |||||||
| OH-2′ | 13.2, s | |||||||
| OH-4′ | 6.81, s | |||||||
| OH-7′ | 13.59, s | |||||||
| OH-7 | 14.15, s | |||||||
Figure 2Correlation of 1H-1H-COSY and HMBC compounds 1–6.
1H NMR and 13C NMR spectral data for compounds 5-6 (δ in ppm, J in Hz).
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | — | 7.15, d (1H, 8.5) | 128.72 | |
| 2 | — | 198.16 | 6.52, d (1H, 8.5) | 110.83 |
| 3 | 7.96, d (1H, 10.1) | 143.48 | — | 147.76 |
| 4 | 7.71, d (1H, 10.1) | 126.69 | — | 115.84 |
| 4a | — | 105.95 | — | 154.59 |
| 5 | 143.41 | — | — | |
| 6 | 6.41, s | 105.82 | 3.59, t (1H, 10.2) | 69.37 |
| 6 | — | — | 4.31, dd (1H, 4.9, 10.2) | 69.55 |
| 6a | — | — | 3.50, (1H, m, 10.2, 7.0, 5.0) | 40.48 |
| 6b | — | — | — | 116.56 |
| 7 | 168.38 | 6.73, s | 108.07 | |
| 8 | 105.08 | — | 152.51 | |
| 8a | 159.81 | — | — | |
| 9 | — | 163.17 | ||
| 10 | 6.49, s | 99.01 | ||
| 10a | — | 154.59 | ||
| 11a | 5.20, d (1H, 7.0) | 77.75 | ||
| 11b | — | 112.23 | ||
| 1′ | 204.19 | 3.43, d (2H, 8) | 24.61 | |
| 2′ | 7.31, d (1H, 15.4) | 142.54 | 5.29, d (1H, 8) | 121.62 |
| 3′ | 7.47, d (1H, 15.4) | 132.26 | — | 137.49 |
| 4′ | — | 132.68 | 1.81, 3H, s | 18.75 |
| 5′ | 6.26, 1H, m | 108.31 | 1.70, 3H, s | 24.61 |
| 6′ | — | 166.38 | — | — |
| 7′ | 6.32 (1H, dd, 1.7, 1.7) | 105.79 | ||
| 8′ | — | 166.12 | ||
| 9′ | 6.40, 1H, m | 101.24 | ||
| OMe-3 | — | — | 3.11, s | 55.57 |
| OMe-8 | — | — | 3.35, s | 60.64 |
| OH-9 | — | — | 8.12, s | — |
Scavenging effects of 1–5 on different in vitro assays.
| Assay | Scavenging effects (IC50
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
| Reference compounds | |
| DPPH radical | 39.39 ± 2.57 | 83.43 ± 5.11 | 12.49 ± 3.98 | 10.21 ± 4.23 | 15.45 ± 7.51 | Ascorbic acid |
| NO radical | 48.69 ± 6.27 | 85.04 ± 4.83 | 30.29 ± 3.48 | 25.47 ± 4.70 | 31.52 ± 2.93 | Ascorbic acid |
| O2 •− | 8.87 ± 1.05 | 18.86 ± 2.19 | 6.03 ± 0.39 | 5.76 ± 0.73 | 7.21 ± 3.22 | Ascorbic acid |
| Hydroxyl radical | 44.13 ± 4.28 | 62.34 ± 3.78 | 37.45 ± 2.58 | 33.17 ± 6.83 | 36.52 ± 5.40 | Ascorbic acid |
| Hydrogen peroxide | 91.81 ± 4.57 | 143.13 ± 7.55 | 80.73 ± 6.76 | 87.68 ± 9.43 | 101.03 ± 10.88 | Ascorbic acid |
|
| ||||||
| Scavenging effects (%) | ||||||
|
| ||||||
| Chelating activity | 76 | 43 | 89 | 84 | 85 | Ascorbic acid |
| Peroxidationof BSA | Ascorbic acid | |||||
| 100 | 30 | 25 | 36 | 38 | 32 | |
| 200 | 55 | 48 | 60 | 64 | 59 | |
| 300 | 83 | 65 | 90 | 97 | 92 | |
|
| ||||||
| TEAC (nM) | ||||||
|
| ||||||
| TEAC: ABTS | 28.11 ± 2.48 | 49.51 ± 4.15 | 19.38 ± 3.29 | 16.23 ± 2.15 | 20.34 ± 2.17 | Curcumin |
The data represent the means ± SD of three determinations. IC50: concentration required to inhibit 50% of the activity; DPPH: 2,2-diphenyl-1-picrylhydrazyl; O2 •−: superoxide radical; TEAC: ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) radical scavenging capacity in Trolox equivalence (nanomoles); BSA: bovine serum albumin; Trolox: 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.
Effect of 1–5 on cellular oxidation stress reduction activity.
| Group | DCF fluorescence (%) |
|---|---|
| Blank | 0.7 ± 0.004 |
| Control | 89.2 ± 3.32 |
|
| |
| 10 | 79.4 ± 5.32 |
| 50 | 64.3 ± 1.83 |
| 100 | 44.6 ± 4.39 |
|
| |
| 10 | 86.5 ± 6.17 |
| 50 | 68.4 ± 5.38 |
| 100 | 55.2 ± 7.35 |
|
| |
| 10 | 72.3 ± 7.09 |
| 50 | 60.8 ± 4.21 |
| 100 | 39.6 ± 3.19 |
|
| |
| 10 | 69.8 ± 3.26 |
| 50 | 52.1 ± 2.99 |
| 100 | 35.1 ± 2.67 |
|
| |
| 10 | 73.4 ± 5.16 |
| 50 | 58.5 ± 6.43 |
| 100 | 38.3 ± 4.29 |
| Ascorbic acid 25 | 19.1 ± 1.46 |
Fluorescence (488 nm (excitation) and 535 nm (emission)) was finally quantified after 24 h incubation. Data is shown as mean ± SD of the experiments (3 replicates each).
Antioxidative status of mice and biochemical parameters at the end of the experimental period.
| Organ | Group | SOD | CAT | CSH-Px | GSH | MDA |
|---|---|---|---|---|---|---|
| (U/min−1) | (U/s−1) | (U/mL−1) | (U/mL−1) | (nmol/mL−1) | ||
| Kidney | N | 2.2 ± 0.34a | 0.74 ± 0.005b | 68.65 ± 2.43a | 25.27 ± 4.31a | 29.12 ± 3.57a |
| MD | 2.8 ± 0.26b | 0.59 ± 0.002c | 56.41 ± 5.19b | 5.29 ± 1.84c | 25.60 ± 5.16b | |
| MD + | 3.6 ± 0.34c | 0.79 ± 0.005b | 71.65 ± 6.73c | 16.21 ± 1.53b | 27.93 ± 4.52a | |
| MD + | 3.1 ± 0.39b | 0.76 ± 0.006a | 67.62 ± 4.10a | 13.07 ± 3.76a | 26.62 ± 1.47a | |
| MD + | 3.7 ± 0.39c | 0.82 ± 0.006a | 73.80 ± 6.14b | 17.23 ± 1.95b | 28.18 ± 3.52c | |
| MD + | 3.8 ± 0.42c | 0.84 ± 0.009a | 79.37 ± 4.42a | 19.87 ± 2.25c | 29.14 ± 5.32c | |
| MD + | 3.7 ± 0.39c | 0.82 ± 0.004a | 74.26 ± 5.28a | 19.01 ± 4.78c | 28.01 ± 4.11c | |
|
| ||||||
| Liver | N | 6.5 ± 0.18a | 0.82 ± 0.011a | 99.41 ± 6.16a | 48.76 ± 4.84a | 26.35 ± 4.25a |
| MD | 5.8 ± 0.13b | 0.58 ± 0.005c | 39.34 ± 5.63c | 26.48 ± 2.60b | 23.78 ± 2.17b | |
| MD + | 6.2 ± 0.72a | 0.71 ± 0.006b | 79.59 ± 3.54a | 40.63 ± 3.62c | 25.77 ± 2.83a | |
| MD + | 6.0 ± 0.28a | 0.65 ± 0.004a | 51.24 ± 6.10a | 35.89 ± 4.29c | 24.21 ± 4.76a | |
| MD + | 6.3 ± 0.51a | 0.73 ± 0.003b | 90.21 ± 3.29b | 44.21 ± 7.36a | 26.53 ± 2.80a | |
| MD + | 6.4 ± 0.73a | 0.79 ± 0.005a | 93.26 ± 5.17b | 47.02 ± 5.42c | 27.91 ± 5.52a | |
| MD + | 6.1 ± 0.45a | 0.76 ± 0.002a | 89.38 ± 6.35b | 44.32 ± 6.15a | 27.22 ± 5.16a | |
|
| ||||||
| Pancreas | N | 4.03 ± 0.37a | 0.74 ± 0.007a | 359.56 ± 4.67a | 51.26 ± 3.35a | 28.56 ± 5.42a |
| MD | 2.90 ± 0.67c | 0.65 ± 0.003c | 325.39 ± 6.23b | 19.48 ± 1.84b | 24.21 ± 3.43b | |
| MD + | 3.70 ± 0.49b | 0.72 ± 0.004b | 342.29 ± 4.67c | 43.17 ± 3.27c | 26.55 ± 2.67ac | |
| MD + | 3.06 ± 0.30a | 0.69 ± 0.005a | 330.56 ± 7.52b | 30.84 ± 5.63d | 25.19 ± 6.54a | |
| MD + | 3.80 ± 0.59b | 0.73 ± 0.005b | 346.99 ± 6.43c | 45.80 ± 3.52c | 26.56 ± 2.90ac | |
| MD + | 3.89 ± 0.47b | 0.75 ± 0.008a | 350.48 ± 5.39a | 47.22 ± 5.42d | 27.84 ± 4.53a | |
| MD + | 3.12 ± 0.62c | 0.76 ± 0.009a | 349.14 ± 5.84d | 45.74 ± 6.21d | 27.18 ± 5.84a | |
Each value represents the mean ± SEM from 6 rats. Values within columns bearing the same lower case letters (a, b, c, and d) are not different at p < 0.05 and are not in any particular order. Normal control (N) and diabetic control (MD).
Effects of 1–5 on serum enzyme levels in hyperglycaemic and normal mice.
| Group | Glucose | SGOT | SGPT | ALP | TB | Total protein |
|---|---|---|---|---|---|---|
| (mg/dL) | (IU/L) | (IU/L) | (KA units) | (mg/dL) | (g/dL) | |
| Normal control | 99.4 ± 5.67 | 140.18 ± 8.15 | 99.31 ± 4.59 | 30.17 ± 3.52 | 0.65 ± 0.07 | 8.1 ± 2.14 |
| Control diabetic MD | 256.7 ± 8.43a | 234.23 ± 5.71a | 200.06 ± 7.34a | 71.86 ± 5.48a | 0.46 ± 0.06a | 5.1 ± 1.6a |
| MD + | — | 168.87 ± 5.15b | 135.61 ± 6.82b | 54.78 ± 1.98b | 0.51 ± 0.07b | 6.3 ± 1.84b |
| MD + | — | 182.04 ± 4.17b | 145.71 ± 6.04b | 63.62 ± 4.26b | 0.49 ± 0.04b | 5.9 ± 0.98b |
| MD + | — | 163.61 ± 7.48b | 129.72 ± 4.48b | 50.09 ± 3.56b | 0.55 ± 0.05b | 6.8 ± 2.74b |
| MD + | — | 150.29 ± 6.41b | 122.27 ± 5.67b | 45.30 ± 2.92b | 0.58 ± 0.03b | 7.1 ± 2.31b |
| MD + | — | 156.52 ± 5.42b | 128.30 ± 7.03b | 48.41 ± 2.68b | 0.56 ± 0.08b | 6.9 ± 1.95b |
Each value represents the mean ± SEM (n = 6 rats). a p < 0.001 compared with normal control group and b p < 0.001 compared with MD control group. ALP: alkaline phosphatase; SGOT: serum glutamate oxaloacetate transaminase; SGPT: serum glutamate; TB: total bilirubin.
Effect of 1–5 on malondialdehyde concentration in liver and kidney of normal and diabetic mice.
| Groups | TBARS ( | |
|---|---|---|
| Liver | Kidney | |
| Normal control | 0.99 ± 0.08 | 1.9 ± 0.04 |
| MD control | 1.60 ± 0.09a | 2.7 ± 0.06a |
| MD + | 1.07 ± 0.06b | 2.0 ± 0.09b |
| MD + | 1.21 ± 0.02b | 2.3 ± 0.07b |
| MD + | 0.99 ± 0.07b | 1.9 ± 0.08b |
| MD + | 0.97 ± 0.03b | 1.8 ± 0.04b |
| MD + | 0.95 ± 0.05b | 1.6 ± 0.06b |
All values are expressed as mean ± SEM, n = 10. a p < 0.05 when compared to normal control group. b p < 0.01 when compared to diabetic control group.